BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

- In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing hypercalciuria - Rapid and sustained impact of...

Related Keywords

United States ,American ,Vikram Bali ,Scott Adler ,Rachel Gafni ,Pamerican Society For Bone ,Mineral Research ,European Union ,National Institutes Of Health ,Securities Exchange ,Geisinger Health System ,Craniofacial Research ,Nasdaq ,Bridgebio Pharma Inc ,Linkedin ,Drug Administration ,Twitter ,Endocrine Society Meeting ,Bio Pharma ,New England Journal ,National Institutes ,National Institute ,American Society ,Fast Track Designation ,Orphan Drug ,Autosomal Dominant Hypocalcemia Type ,United Kingdom Biobank ,Securities Act ,Securities Exchange Act ,Risk Factors ,Annual Report ,Bio Media Contact ,Markets ,